Clinical Trial Update: TLK286 (Telcyta) in Combination With Cisplatin for Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) [Phase 1, Phase 2]

View source ↗

Summary

A completed Phase 1/2 study evaluated TLK286 (Telcyta) in combination with cisplatin for locally advanced or metastatic non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• CISPLATIN (cisplatin)
• Telcyta (TLK286)

Snippet

Sponsor: Telik | Conditions: Non-small Cell Lung Cancer | Phase 1, Phase 2 | Status: COMPLETED